Please assess the completion status of the following clinical trial:

Trial Title: Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, age ≥ 18 years with confirmed diagnosis of CF, homozygous for the F508del-CFTR mutation based on historical results generated by Ambry Genetics within the past two years or if unavailable, confirmed by testing done within the past 28 days~2. Sweat chloride ≥ 60 (milliequivalents) mEq/L, by quantitative pilocarpine iontophoresis test (QPIT) at screening~3. Weight ≥ 40 kg at screening~4. Forced expiratory volume (FEV1) ≥ 40% of predicted normal for age, gender, and height (Hankinson standards) pre- or post-bronchodilator value, at screening~5. Oxygen saturation by pulse oximetry ≥ 90% breathing ambient air, at screening~6. Hematology, clinical chemistry and urinalysis results with no clinically significant abnormalities that would interfere with the study assessments at screening~Exclusion Criteria:~1. Any acute infection, including acute upper or lower respiratory infections and pulmonary exacerbations that require treatment or hospitalization within 2 weeks of Study Day 1~2. Any change in chronic therapies for CF lung disease (e.g., Ibuprofen, Pulmozyme®, hypertonic saline, Azithromycin, Tobi®, Cayston®) within 4 weeks of Study Day 1~3. Blood hemoglobin \< 10 g/dL at screening~4. Serum albumin \< 2.5 g/dL at screening~5. Abnormal liver function defined as ≥ 3 x upper limit of normal (ULN) in 3 or more of the following: aspartate aminotransferase (AST), alanine aminotransferase (ALT), g-glutamyl transferase (GGT), alkaline phosphatase (ALP), or total bilirubin at screening~6. History of abnormal renal function (creatinine clearance \< 50 mL/min using Cockcroft-Gault equation) within a year of screening~7. History, including the screening assessment, of ventricular tachycardia or other ventricular arrhythmias~8. History, including the screening assessment, of prolonged cardiac QT interval and/or QTcF (QT with Fridericia's correction) interval (\> 450 msec)~9. History of solid organ or hematological transplantation~10. History of alcohol abuse or drug abuse (including cannabis, cocaine, and opioids) in the year prior to screening~11. Use of continuous (24 hr/day) or nocturnal supplemental oxygen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 - 50 mg (Type: EXPERIMENTAL): Every 12 hour oral dosing of N91115 for 28 days
- Group 2 - 100 mg (Type: EXPERIMENTAL): Every 12 hour oral dosing of N91115 for 28 days
- Group 3 - 200 mg (Type: EXPERIMENTAL): Every 12 hour oral dosing of N91115 for 28 days
- Group 4 - Placebo (Type: PLACEBO_COMPARATOR): Every 12 hour oral dosing of placebo comparator for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).